Key Highlights
- StrokeDx closes $5M in Series Seed Prime funding, led by DigiTx Partners.
- David J. Kim, MD, joins StrokeDx’s board of directors.
- Funds to support clinical validation and commercial expansion of innovative stroke technology.
- Technology developed by Shane Shahrestani, MD, PhD, at Caltech.
- Focus on portable, non-invasive cerebrovascular monitoring.
Source: Business Wire
Notable Quotes
- “This funding enables us to scale our detection and monitoring solution, empowering physicians and their patients with an effective tool for point-of-care cerebrovascular monitoring.” – Alexander Ballatori, Co-Founder and CEO at StrokeDx
- “We believe in the potential of StrokeDx’s technology to change the diagnostic paradigm and ultimately improve outcomes for stroke patients.” – David J. Kim, MD, Managing Director at DigiTx Partners
SoHC's Take
The successful closing of $5 million in Series Seed Prime funding marks a significant milestone for StrokeDx, positioning the company to further validate and expand its pioneering stroke detection technology. The involvement of leading investors such as DigiTx Partners and Freeflow Ventures underscores the confidence in StrokeDx’s innovative approach to cerebrovascular monitoring. With the addition of David J. Kim, MD, to the board, StrokeDx is well-equipped to drive forward its mission of improving stroke outcomes through early detection and rapid monitoring. This funding not only highlights the potential impact on healthcare accessibility and equity but also solidifies StrokeDx’s role in transforming stroke diagnostics and prevention on a global scale.
